SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001628280-23-012160
Filing Date
2023-04-20
Accepted
2023-04-20 08:47:27
Documents
19
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 20-F/A inpha-20221231.htm   iXBRL 20-F/A 59418
2 EX-4.9 exhibit49-20xfa.htm EX-4.9 7765019
3 EX-12.1 exhibit121-20xfa.htm EX-12.1 4549
4 EX-12.2 exhibit122-20xfa.htm EX-12.2 4293
9 exhibit491aa.jpg GRAPHIC 4226735
10 exhibit492aa.jpg GRAPHIC 4432796
  Complete submission text file 0001628280-23-012160.txt   19911679

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inpha-20221231.xsd EX-101.SCH 3047
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT inpha-20221231_def.xml EX-101.DEF 23113
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inpha-20221231_lab.xml EX-101.LAB 48505
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inpha-20221231_pre.xml EX-101.PRE 26173
13 EXTRACTED XBRL INSTANCE DOCUMENT inpha-20221231_htm.xml XML 22273
Mailing Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009
Business Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009 33430303030
Innate Pharma SA (Filer) CIK: 0001598599 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: 20-F/A | Act: 34 | File No.: 001-39084 | Film No.: 23831498
SIC: 2836 Biological Products, (No Diagnostic Substances)